期刊论文详细信息
Antibodies
Molecular Engineering of Therapeutic Cytokines
Rodrigo Vazquez-Lombardi1  Brendan Roome2 
[1] id="af1-antibodies-02-00426">Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, Sydney, New South Wales 2010, Austral
关键词: immunotherapy;    cytokines;    protein engineering;    immunocytokines;    fusion proteins;   
DOI  :  10.3390/antib2030426
来源: mdpi
PDF
【 摘 要 】

Over the past three decades, a large body of work has been directed at the development of therapeutic cytokines. Despite their central role in immune modulation, only a handful of cytokine therapeutics has achieved regulatory approval. One of the major challenges associated with the therapeutic use of cytokines relates to their short serum half-life and low bioavailability. High doses are required to overcome these problems, which often result in dose-limiting toxicities. Consequently, most cytokines require protein engineering approaches to reduce toxicity and increase half-life. For this purpose, PEGylation, fusion proteins, antibody complexes and mutagenesis have been utilized. Here, we summarize past, recent and emerging strategies in this area.

【 授权许可】

CC BY   
© 2013 by the authors; licensee MDPI, Basel, Switzerland.

【 预 览 】
附件列表
Files Size Format View
RO202003190035132ZK.pdf 342KB PDF download
  文献评价指标  
  下载次数:4次 浏览次数:8次